Skip to main content

Table 1 Summary of study characteristics and costs per DALY averted for interventions targeting all ages

From: Cost-effectiveness analysis of malaria interventions using disability adjusted life years: a systematic review

References Publication year Country/region Malaria intervention Main data sources Life tables source Cost-effectiveness threshold used Cost-effectiveness ratio (cost per DALY averted in US $) DALYs averted per $ 1 million spent on intervention
[1] 1999 Brazil Case treatment, vector control and insecticide spraying Malaria control program GBD study Not stated $69 14,493
[2] 1999 Model ITNs Model
Assumptions
GBD study US$ 30 and US$ 150 <$150 <6667
[3] 2001 Zambia Environmental management, treatment and mosquito nets Malaria control program data West African model life table Not stated $524–591 over a period of 3–5 years 1799
[4] 2002 Zambia Integrated malaria control (environmental management, rapid diagnosis and treatment and the use of bed nets Census
Hospital patient records
West African model life table Not stated $36.90 (average) 27,100
[5] 2005 Multi-country Combination of strategies Reports
WHO databases
Expert opinion
Published data
WHO life tables Not stated $10–100 18,182
[6] 2006 Kenya Malaria home management
Educational programme
Census
Published data
Surveys
Model US$ 30 and US$ 150 <$30 <33,333
[7] 2006 Non-specific Case management Simulation model Ethiopian life table Not stated Not specified  
[8] 2008 Sub-Saharan Diagnostic methods Published and unpublished data
Expert opinion
West African life table US$ 150 >US$ 70 (95% certainty and $40% malaria prevalence) >14,286
[9] 2008 Multi-country IRS
ITNs
Published data
ITN and IRS programmes
Not specified US$ 30 and US$ 150 $56 (calculated average) 17,857
[10] 2009 Kenya and Uganda Early detection system Health facilities   US$ 30 and US$ 150 <$150 <6667
[11] 2009 Non-specific Vaccines (PEV, BSV, MSTBV and combinations) Published data
WHO estimates
Ethiopian life table Not stated $31 (pre-erythrocytic vaccine at $2 dose) 32,258
$13.50 (blood stage vaccine at $2 dose) 74,074
[12] 2009 Eritrea ITNs Published data
National malaria control programme
WHO US$ 30 and US$ 150 $13–44 34,483
[13] 2010 Model Pre-referral rectal antimalarial treatment Published data
World malaria report
Region-specific US$ 30 and US$ 150 $5 (in SSA) 200,000
[14] 2011 Model Pre-erythrocytic malaria
Vaccine
  Ethiopian life table US$ 30 and US$ 150 I$207 (ceiling ratio) 4831
[15] 2012 Kenya LLINs Published data
Epidemiologic data
  Not stated <$20 <50,000
[16] 2013 Experimental
Model
LLINs Published studies Country specific US$ 30 and US$ 150 US$ 235.28 4250
[17] 2013 Model LLINs Simulation Country specific US$ 30 and US$ 150 US$ 235.28 4250
[18] 2013 Multi-country Pre-erythrocytic Vaccine UN population division
WHO
WHO 1–3 times GDP per capita $56 17,857
[19] 2014 Tanzania Larviciding Malaria control program GBD 2010 1-3 times GDP per capita $ 43-$ 545 (depending on scenario) 3401
[20] 2014 Kenya Combined interventions (IRS, LLINs, AL Published data
Survey
Ethiopian life table Not stated $4.29–$55.70 (depending on the intervention) 33,339
[21] 2015 Multi-country Dihydroartemisinin–piperaquine (DP)
Artemether–lumefantrine (AL)
Multi-centre clinical trial WHO life table Not stated $ 5 (for DP) 200,000
[22] 2015 Myanmar RDTs Published data
Management information system
World Bank
Global burden of study (2012)
Not stated $639a 1565
[23] 2015 China Malaria elimination Published data
Infectious disease information system
Chinese life table Not stated Not specified Not applicable
[24] 2016 Model RTS,S/AS01 malaria vaccine   Ethiopian life table Not stated $ 80 (3 dose schedule at $5 per dose) 12,500
  1. aSubsidy with information, education and counselling compared to no intervention